Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Top Pharma List methodology page

  • The Top Pharma List is based on data provided by research and consulting firm GlobalData.
  • The current version of the data ranks companies based on information from GlobalData Pharma Intelligence Center’s Sales Analytics Database, as shown on July 7, 2017.
  • Figures for the period 2018-23 are a forecast, but only show the performance of those companies featured in the 2017 ranking.

US/Japan/Europe Rx

  • These lists rank the top companies based on geographic-specific sales.

Products

  • Product sales are mapped to the parent company, rather than subsidiary companies, as they are reported in the annual reports of the parent company itself.
  • For example, ViiV Healthcare (whose partners include Pfizer and Shionogi) operates as a subsidiary of GSK, so sales for ViiV’s Triumeq have been attributed to GSK.
  • Similarly, Xtandi is attributed to Astellas not Pfizer and Imbruvica is attributed to AbbVie rather than Johnson & Johnson.
  • Finally, sales of Eliquis are reported separately by both Bristol-Myers Squibb and Pfizer and so appears twice in the top product ranking, as does Enbrel with sales as reported by Amgen and Pfizer.

Therapy area sales

  • The sales data provided are not indication-specific where drugs are approved, or in development, for multiple indications. Instead they’re based on GlobalData’s Key Therapy Area classification, which places products into a single therapeutic area based on its corporate positioning and/or mechanism of action.
  • However, product sales may contribute to more than one sales segment, eg biologics and oncology, in which can sales segments for a company may add up to more than its total sales.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics